       Document 1070
 DOCN  M9621070
 TI    Neutralization of primary HIV-1 isolates by anti-envelope monoclonal
       antibodies.
 DT    9602
 AU    D'Souza MP; Milman G; Bradac JA; McPhee D; Hanson CV; Hendry RM;
       Division of AIDS, National Institute of Allergy and Infectious;
       Diseases, National Institutes of Health, Bethesda, Maryland; 20892, USA.
 SO    AIDS. 1995 Aug;9(8):867-74. Unique Identifier : AIDSLINE MED/96014959
 AB    OBJECTIVE: To evaluate human monoclonal antibodies (MAb) for
       neutralizing activity against primary HIV-1 isolates in peripheral blood
       mononuclear cells. DESIGN: Neutralization activity data were obtained
       from 11 laboratories on a coded panel consisting of six human MAb to HIV
       envelope V3, CD4-binding region or gp41. Hyperimmune globulin against
       HIV-1 and normal human immunoglobulin G were supplied as controls. Each
       laboratory received pre-titered virus for use in the studies. METHODS:
       Each laboratory measured neutralization of the MAb against laboratory
       strain HIVMN, genomic clone HIVJR-CSF, two subtype B and one subtype D
       primary isolates. RESULTS: The titers of the centrally supplied virus
       stocks as determined by re-titration or back-titration varied among
       laboratories and were generally 10-100-fold less than provided. The
       neutralizing activity of each MAb varied by as much as a 1000-fold among
       laboratories. These differences may result from varying sensitivity in
       neutralization assay protocols and the differing susceptibility of
       primary cells to infection with HIV-1. CONCLUSIONS: To consolidate the
       data from multiple laboratories, the neutralization titers were compared
       by classifying antibodies as neutralizing if the antibody concentration
       for 50% virus inhibition was < or = 10 micrograms/ml. By this criterion,
       the CD4-binding region and gp41 MAb neutralized all four subtype B
       viruses and the subtype D isolate in a few of the laboratories. The V3
       MAb neutralized only HIVMN and the closely related HIVJR-CSF viruses.
 DE    *Antibodies, Monoclonal  Antigens, CD4/IMMUNOLOGY  Comparative Study
       Gene Products, env/*IMMUNOLOGY  Human  *HIV Antibodies  HIV Envelope
       Protein gp120/IMMUNOLOGY  HIV Envelope Protein gp41/IMMUNOLOGY
       HIV-1/CLASSIFICATION/*IMMUNOLOGY/ISOLATION & PURIF  In Vitro
       Leukocytes, Mononuclear/VIROLOGY  Neutralization Tests  Peptide
       Fragments/IMMUNOLOGY  Support, Non-U.S. Gov't  Support, U.S. Gov't,
       P.H.S.  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

